GW suffers major blow as US sinks bid to patent cannabinoids for epilepsy
Cannabis Law Report
JANUARY 15, 2019
British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.
Let's personalize your content